The costimulatory molecule B7.1 provides a second signal critical for T cell activation. The distribution of this integral membrane protein is restricted to certain tissues where its level of expression is modulated by multiple exogenous stimuli. To identify the molecular basis for specificity and inducibility, the chromatin configuration of the human B7.1 gene was examined in intact nuclei from various cell types. The identification of a tissue-specific deoxyribonuclease I hypersensitive site ,',~3kb upstream of the transcription start site led to the characterization of a cell type-specific enhancer region. This 183-bp region was both cell type specific and responsive to two distinct stimuli, lipopolysaccharide and dibutyryl cAMP, known to regulate B7.1 expression. Deletional and site-directed mutagenesis revealed the presence of multiple functionally critical ds elements within this region, one of which was a nuclear factor (NF)-gB consensus sequence. In B7.1-positive B cells, this element bound several members of the NF-KB family, transcription factors already implicated in signal transduction pathways relevant to B7.1 expression. This is the first description, to our knowledge, of regulatory elements that control expression of a gene encoding a B7 costimulatory molecule.
Summary
The costimulatory molecule B7.1 provides a second signal critical for T cell activation. The distribution of this integral membrane protein is restricted to certain tissues where its level of expression is modulated by multiple exogenous stimuli. To identify the molecular basis for specificity and inducibility, the chromatin configuration of the human B7.1 gene was examined in intact nuclei from various cell types. The identification of a tissue-specific deoxyribonuclease I hypersensitive site ,',~3kb upstream of the transcription start site led to the characterization of a cell type-specific enhancer region. This 183-bp region was both cell type specific and responsive to two distinct stimuli, lipopolysaccharide and dibutyryl cAMP, known to regulate B7.1 expression. Deletional and site-directed mutagenesis revealed the presence of multiple functionally critical ds elements within this region, one of which was a nuclear factor (NF)-gB consensus sequence. In B7.1-positive B cells, this element bound several members of the NF-KB family, transcription factors already implicated in signal transduction pathways relevant to B7.1 expression. This is the first description, to our knowledge, of regulatory elements that control expression of a gene encoding a B7 costimulatory molecule.
E
ffective activation of T lymphocytes requires two signals from APCs (for a review see reference 1). The first signal is delivered upon the binding of the clonally distributed TCR to MHC-foreign antigen complexes on APCs. This interaction results in the phosphorylation of cellular tyrosine kinases and the induction of gene expression (2, 3) . The second signal is provided by the interaction of costimulatory molecules on T cells with their ligands on APCs (4) . The delivery of signal one in the absence of signal two can lead to T cell paralysis or anergy (5) (6) (7) .
Of the known costimulatory molecules, the B7 family of proteins is arguably the most potent. This family consists of at least two members, B7.1 (CDS0) (8) and B7.2 (CD86) (9) (10) (11) , which interact with similar affinity with their counterreceptors, CD28 and CTLA4, on T cells, although their affinity for CTLA4 is substantially greater than for CD28 (12, 13) . Blocking the interaction of the B7 molecules by excess soluble CTLA4 during T cell activation leads to hyporesponsiveness (14) . Not surprisingly, B7.1-deficient mice have substantially reduced immune responses (15) . Blockade of B7.1 by mAb injection leads to amelioration ofautoimmune experimental allergic encephalitis, a murine model of multiple sclerosis (16) , and prevents xenograft rejection (17) .
The B7.1 and B7.2 molecules have similar but not identical tissue distribution patterns. Both proteins are expressed on dendritic cells, and B7.1 is expressed on activated but not resting T cells (18, 19) . Resting B cells express low levels of B7.2 but not B7.1 whereas upon activation, B cells express substantial levels of both proteins (10, 20) . Similarly, macrophages constitutively express B7.2 and can be induced to express higher levels of B7 proteins upon IFN-~/ treatment (21) . In general, in mice, cell surface B7.2 levels are higher than B7.1 levels, and the kinetics of induction of B7.2 are faster than those of B7.1 (22, 23) .
A large number of stimuli can induce B7.1 expression on resting, surface-negative B cells. These include the cytokine IL-4 (24), Abs to the B cell Ig receptor (23) , hgation of the B cell activation molecule CD40 (25) , the mitogens LPS and dextran sulfate (23) , transformation by EBV (26) , and agents that activate protein kinase A, such as dibutyryl cyclic AMP (db-cAMP) 1 (27, 28) . Since resting B cells do not contain detectable transcripts for B7.1, it is likely that such induction occurs primarily at the transcriptional level. Similarly, B7.1-negative monocytes become B7.1 positive 1Abbreviations used in this paper: db-cAMP, dibutyl cyclic AMP; EMSA, electrophoretic mobility shift assay; HTLV-1, human T cell leukemia vires type-l; NF-KB, nuclear factor r,B; NIB, nuclear isolation buffer; tk, thymidine kinase.
after treatment with IFN-'y (29), as do resting T cells upon activation by antigen or transformation by human T cell leukemia virus type-1 (HTLV-1) (26) . Many of these stimuli have been shown to activate the nuclear factor (NF) KB transcription factor in other systems.
The cDNAs encoding both human and mouse B7.1 genes have been isolated (8, 30) . Using the human cDNA as probe, four transcripts sized 1.7, 2.9, 4.2, and 10 kb were detected in normal and neoplastic B cells. The 2.9 kb transcript was the major species in anti-Ig-activated B cells whereas the 1.7-kb transcript predominated in B tumor cell lines, such as the Raji cell line (30) . In the mouse, three transcripts, 2.2, 3.9, and 10 kb were detected in spleen and transformed B cells (8) . The molecular basis for the variation in transcript lengths has not been determined. The genomic organization of both the human and mouse genes has also been reported (31, 32) . In humans, the B7.1 locus spans ~32 kb. A primer extension analysis of mRNAs from Raft and CHI B cells has shown that transcription of both human and mouse B7.1 initiates within about 60 nucleotides upstream of the 5' end of the existing cDNA clones (31, 32) . However, no obvious promoter elements were observed in the 5' flanking region abutting the putative transcription start sites. Recently, Borrielio et al. (33) used RACE (5' reverse amplification cDNA ends) on RNA isolated from CH1 B cells to extend the 5' end of the previously published roB7.1 cDNA by 1.5 kb, suggesting that an additional 5' untranslated sequence may account for the variation in transcript length.
In this report, we describe the analysis of the human B7.1 promoter. We provide evidence for an enhancer region located ~3 kb upstream of the first exon which determines both cell type specificity and inducibility by certain stimuli. Linker-scanning mutagenesis of this region revealed the presence ofa NF-KB consensus binding site and several additional sites whose integrity was critical for enhancer function.
Materials and Methods
Isolation, Cloning, and Sequencing of the 5' Flanking Region of the B7. I Gene. A full-length human B7.1 cDNA was used to screen a leukocyte genomic DNA library in k EMBL-3 (a gift of Dr. S. Orkin, Children's Hospital, Boston, MA) (34) . The screening procedure was as described (35) . The DNA from 10 positive clones was prepared, digested with restriction endonucleases, and subjected to agarose gel electrophoresis. The separated DNA fragments were transferred to nitrocellulose filters and probed with 32p-labeled oligonucleotides representing sequences derived from different domains of the B7.1 gene. The procedures ofprehybridization, hybridization, and washing of filters were as described (30) .
One clone, kUT-1, hybridized to probes from the first and second exons of the B7. 1 gene. The DNA of this clone was further mapped by digestion with restriction endonucleases, and various subfragments recovered from agarose gels were subcloned into pBluescript KS (Stratagene Inc., LaJolla, CA). A 3.3-kb SacI subclone containing the first exon was used to generate a series of nested deletions using the Erase-a-Base kit (Promega, Madison, WI). The overlapping deletion clones were sequenced on both strands using dye-labeled terminator/Taq polymerase chemistry and analyzed on an automated fluorescence DNA sequencer (Applied Biosystems, Inc., Foster City, CA).
In addition, a 2.4-kb BamHI-SacI fragment was sequenced by the dideoxynucleotide chain-termination/extension method (36) and Sequenase (United States Biochemical Corp., Cleveland, OH) using B7.1-specific oligonucleotide primers. The sequence was analyzed with the Genetic Computer Group (GCG) package (37) and compared with those in the GenBank database.
Cell Lines. Human EBV-transformed B cell lines BL30, EBV5, and SKW were obtained from Dr. J. Fingeroth (Dana-Farber Cancer Institute), the Nalm6-transformed pre-B cell line was provided by Dr. J. Ritz (Dana-Farber Cancer Institute), and the BA cell line came from Dr. S. Lederman (Columbia University, New York). Other human cell lines, including the epitheloid carcinoma HeLa, the hepatocellular carcinoma HepG2, the leukemic T cell line Jurkat, the small cell lung carcinoma NCI-H146, the Burkitt lymphoma Raft and EBV-negative Burkitt lymphoma Ramos, and the mouse myeloid cell line M1 were purchased from the American Type Culture Collection (Rockville, MD). The human fibroblast GM00637 was obtained from the Coriell Institute for Medical Research (Camden, NJ). M12.4.1 is a BALB/c B lymphoma cell (38) . HeLa, HepG2, and GM00637 were grown in DME, and all other cells were cultured in RPMI 1640 containing 10 mM Hepes, pH 7.3. All culture media were supplemented with 8% heat-inactivated FCS (HyClone Laboratories, Inc., Logan, UT), 2 mM L-glutamine, 100 U/ml penicillin, 100 b~g/ml streptomycin, and 50 btM 2-ME. The culture medium for M1 also contained 100 b~M nonessential amino acids.
Abs and Flow Cytometry. Anti-hB7.1 mAb 133 (mouse IgM) (39) and anti-mB7.1 mAb 1G10 (rat IgG2a) (27) have been described previously. The mAbs MIgM,K and RIgG2a,K were purchased from PharMingen (San Diego, CA) and used as isotypematched control Abs for human or mouse cells, respectively. Flow cytometry analysis was carried out as described. Briefly, 5 • 10 s cells were incubated with either control Ab or anti-B7.1 mAb at 4~ in HBSS containing 3% BSA and 0.1% NAN3. After washing, the human and mouse cells were stained with FITC-conjugated goat anti-mouse IgM (Tago, Inc., Burlingame, CA) or FITC goat anti-rat IgG (Kirkegaard & Perry Laboratories Inc., Gaithersburg, MD), respectively. The analysis of the cells was performed on a FACS | analyzer (Becton Dickinson & Co., Mountain View, CA).
DNase I Hypersensitive Site Mapping. Isolation and DNase I digestion of nuclei were performed as described (40) . Briefly, 108 cells in log phase were harvested, washed with PBS, and resuspended in 20 ml of ice-cold nuclear isolation buffer (NIB) (15 mM Tris, pH 7.6, 60 mM KC1, 15 mM NaC1, 300 mM sucrose, 5 mM MgC12, and 0.5 mM dithiothreitol [DTT]) containing 0.4% NP-40. Cells were permeablized for 5 rain on ice and centrifuged at 3,000 g for 5 min. Nuclei collected were resuspended in 0.5 ml of NIB and aliquoted into five tubes containing 100 ~1 of NIB plus 0-5 btg of DNase I. After 4 rain at room temperature, the reactions were stopped by addition of 250 ~1 of stop solution (63 mM Tris, pH 8, 2.5 mM EDTA and 1.25% SDS) and 50 ~1 of proteinase K (5 mg/ml). The lysates were incubated overnight at 37~ and proteins were removed by phenol/chloroform extraction. The genomic DNAs isolated were digested by BamHI, SacI, or XhoI and separated by electrophoresis on agarose gels. The gels were blotted and hybridized to a 32p-labeled 295-bp ScaI-BamHl probe, spanning exon 1 of the hB7.1 gene (see Fig. 3 ).
Expression Plasmid Construction. The 3.3-kb Sacl and 5-kb BamHI fragments containing the first exon of the B7.1 gene were released from pBluescript clones and purified from agarose gels. These fragments were inserted into pSyncatI, an expression vector containing a promoterless CAT reporter gene (SynapSys, Burlington, MA). Similarly, the 5-kb BamHl fragment and a 2.8-kb EcoRl fragment containing the DH site B (see Fig. 1 ) were isolated and inserted into pSyncatlI, a vector that contains the minireal herpes virus thymidine kinase (tk) promoter upstream of the CAT reporter gene. Subsequently, these clones were digested with a variety of restriction enzymes to systematically remove different parts of the larger fragments. Subclones of the shorter B7.1 DNA fragments were regenerated by hgation of blunted ends.
Transient Transfections, Induction, and CA T Assays. Raft B cells were transfected by electroporation using an electroporator (BioRad Laboratories, Hercules, CA) as described (41) . HeLa cells were transfected using the standard calcium phosphate technique (42) .
Transfections ofBA B cells andJurkat T cells were performed using DEAE-dextran as described (43) . Briefly, 107 cells were washed in STBS (25 mM Tris, pH 7.4, 137 mM NaC1, 5 mM KC1, 0.6 mM Na2HPO4, 0.7 mM CaCI2, and 0.5 mM MgC12) and resuspended in 1 ml of DEAE-dextran (200 I, tg/rrd) plus 6 Ixg of plasmid DNA. Cells were treated with DEAE-dextran/DNA mixture at room temperature for 30 man, washed once with complete medium, and plated. Cells were harvested 48 h after transfection. M12.4.1 (abbreviated as M12 hereafter) B cells and M1 myeloid cells were transfected using an alternative DEAE-dextran method as previously described (38) . Transfected cells were split equally into two sets of plates and incubated for 24 h. db-cAMP and LPS (both from Sigma Chemical Co., St. Louis, MO) were added to appropriate plates of M12 cells at 30 and 5 b~g/ml, respectively. M1 cells were treated with LPS at 10 ng/ml. Cells were harvested at 18 h after db-cAMP treatment or at 24 h after LPS stimulation. Protein concentration of cell extracts was measured by a protein assay kit (Bio-Rad Laboratories). Equal amounts of protein were used in CAT assays and CAT activity was measured using thinlayer chromatography and liquid scintillation counting. CAT activities of hB7.1 DNA transfections are expressed as fold increase over those of the vector DNA transfections, which were arbitrarily assigned a value of 1.0. All transfections were repeated three times unless otherwise specified. The NF-KB p50 and p65 expression constructs were the gift of Dr. R. Sen (Brandeis University, Waltham, MA).
Mutagenesis of the B7.1 Enhancer. Deletion and linker-scanning mutants of the 183-bp B7.1 enhancer were made by PCR using a panel of synthesized oligonucleotides (oligos). A 665-bp PvulI fragment was isolated from the 183-bp StuI-Apal enhancer pSyncatlI clone and used as the PCP,. template. The template contained pSyncatlI sequences and restrection sites SaclI and BamHI flanking the 5' and 3' end of the enhancer, respectively. Oligos used to construct the 5' and 3' deletions of the enhancer also contained SaclI or BamHI sites, respectively. The 3' portions of the enhancer were obtained by PCR with SaclI-containing oligos and an oligo downstream of the enhancer, whereas the 5' portions were obtained by PCR with BamHI-containing oligos and an oligo upstream of the enhancer. The central portion of the enhancer was obtained by PCR with a pair of the B7.1 oligos flanking the region. PCR. products were digested with Sacll and BamHI and different portions of the enhancer were recovered from agarose gels and recloned into pSyncatII.
Linker-scanning mutagenesis was performed by a modified overlap-extension method as described (44) . In total, 18 unique oligos were designed to contain a 10-bp mutant sequence flanked by 15-bp template sequences on either side. Each oligo was used in PCR. to introduce mutations into a specific 10-bp region of the enhancer without changing the enhancer length. PCR products were digested with SaclI and BamHI, purified from agarose gels, and cloned back into pSyncatlI. DNA sequencing was used to veil@ all mutant and flanking sequences.
Electrophoretic Mobility Shift Assay and Ab Inhibition. Small scale nuclear extracts were prepared from 107 P,.aji B cells as described (45) . An electrophoretic mobility shift assay (EMSA) was performed as previously described (46) in a 10-1xl final volume containing 8 mM Hepes, pH 7.4, 0.3 mM MgC12, 100 mM NaC1, 10 mM KC1, 0.8 mM EDTA, 0.5 mM DTT, and 9% glycerol. Each binding reaction also included 2.5 p~g poly(dI-dC), 2 I~g nuclear extract, and ~2 • 104 cpm of 32p-labeled probe. For Ab inhibition, antisera against p50, p52, p65, c-R.el and R.el-B (Santa Cruz Biotechnology, Santa Cruz, CA) were added at 1 Ixg per reaction. Oligo probes and specific or nonspecific competitors used in EMSA included -2983 to -2959 of the hB7.1 enhancer (5'-GGGAAAGGGGTTTTCCCAGCAGTCA-3'), the NF-KB sequence of the lgK enhancer (5'-CAGAGGGGACTTTC-CGAGA-3') (47), and mutant 3 of the raiL-4 promoter -79 to -60 region (5'-ATAAAATTTGAACATGTAAA-3') (45). The reaction mixtures were separated on a 5% nondenaturing polyacrylamide mini-gel at 80 V for 75 min.
Results and Discussion
Isolation and Characterization of a Human B7.1 Genomic Clone. To isolate a genomic clone encoding the human B7. I gene, a full-length cDNA was used as a probe to screen a leukocyte genomic DNA library in h EMBL-3. From ~6 • 105 plaques screened, 10 clones were isolated that remained positive on tertiary screening. These clones were then analyzed by Southern blot analysis after restriction enzyme digestion and hybridization with 32p-labeled oligonucleotide probes corresponding to sequences derived from different regions of the cDNA. One done, hUT-l, hybridized with probes from the first two exons. Further analysis of this genomic clone revealed that it contained "~14 kb of DNA upstream of the first exon with the restriction map shown in Fig. 1 .
3.9-kb of DNA flanking the first exon was sequenced on both strands (Fig. 2) . A search of this sequence using FASTA of the GCG program in the GenBank database reve;Lled the presence of two alu repetitive sequences (Fig. 1, I and I/) frequently found in flanking regions and introns (48, 49) . No other significant similarities betweeen the hB7. (Fig. 1, II1) To map the location o f the two D H sites more precisely, nuclear D N A from the P, aji cell line was digested with additional restriction endonucleases and hybridized to the same probe used in the DNase I hypersensitivity assays. Digestion with BamHI revealed that sites A and B are ~0 . 3 and 3.2 kb, respectively, upstream o f the BamHI site located 3' to exon 1 (Fig. 3 B) . D H site A, therefore, is located very near the putative transcription start site mapped previously by primer extension. Digestion of DNase I--treated Raji nuclear D N A with SacI revealed a single 0.6-kb fragment representing site A. Since site B is not included in the SacI fragment, it can be mapped between the upstream BamHI and SacI sites to a location ,'-,100 bp 5' to the SacI rite, N 3 kb upstream o f the putative start site. The location o f the two D H sites is shown schematically in Fig. 3 C. (Fig. 4 B) . It was possible that negative regulatory elements within this region were responsible for the absence o f promoter activity. To test whether D H sites A and B represented B7.1 enhancer elements, we therefore subcloned a variety o f fragments encompassing one or both o f these sites into pSyncatII, an expression vector containing a minimal herpes virus tk promoter fused to the C A T reporter gene. Fragments tested in preliminary experiments included a large 5-kb BamHI fragment containing both sites A and B and a smaller 2.8-kb EcoR.I fragment containing only site B. The former had minimal activity whereas the latter gave a threefold increase in C A T activity over the vector alone (not shown). A 3.7-kb PacI-BamHI fragment which included both D H sites was also inactive (Fig. 4 A, lane 12) . A series of restriction endonuclease--generated 5' and 3' deletion fragments were therefore constructed and tested for transcriptional activity (Fig. 4 A) . The 1.9-kb BamHISacI fragment displayed fivefold activity above background (Fig. 4 A, lane 2) and further deletions of this fragment from the 5' end resulted in increasing levels of reporter gene activity (lanes [3] [4] [5] . A further deletion to the ApaI site deleted D H site B and abolished activity (Fig. 4 A, lane 6) , thus establishing the 5' border of the enhancer. Similarly, deletions from the 3' end of the active 486-bp PacI-ApaI fragment (Fig. 4 A, lane 7) to the StuI site 183 bp upstream abolished activity (lane 8). These experiments locahze the enhancer to a 183-bp StuI-ApaI fragment (Fig. 4 A, lane  9) , which is active in both forward and reverse orientations (lanes 5, 11 and 4, 10). Multiple constructs which included the region surrounding D H site A failed to provide evidence for enhancer function in this location (data not shown).
Localization of a Transcriptional Enhancer at D H Site B. The 3.3-kb SacI fragment which includes D H site A did not have transcriptional activity in Raji cells
Because the transcription start site of the hB7.1 gene had been mapped by primer extension to a site 58 nucleotides upstream of the 5' end of the c D N A sequence (31), sequences upstream of the first exon were tested for promoter activity. A 5-kb BamHI fragment and a 3.3-kb SacI fragment containing the first exon were cloned into the promoterless pSyncatl expression vector. Deletion variants of the latter construct generated by restriction enzyme digestion, ranging from N0.5 to 2 kb of upstream sequence were also produced. This series of constructs was tested for promoter activity by transfection into the B7.1-positive R.aji B lymphoma cell line. However, in preliminary experiments, no reporter gene activity was detected. Since Regulation of the B7,1 Gene the failure to detect promoter activity might reflect the presence of dominant negative regulatory elements, a construct containing the 486-bp enhancer upstream of a 468-bp EcoNI-BamHI fragment including D H site A in place of the heterologous tk promoter was made, This construct conferred transcription activity, thus demonstrating that sequences surrounding D H site A can act as a minimal promoter. Neither the 468-bp promoter fragment nor the 486-bp enhancer alone were active (Fig. 4 B) . The absence of transcriptional activity observed with the longer promoter fragments may be due to the presence of negative regulatory elements downstream of the enhancer, possibly including the alu repeat sequences. Indeed, removal of the alu sequences increases promoter activity (Fig. 4 B, compare lanes 5 and 2) . The B7.1 promoter has recently been shown to be transcriptionally active and to contain six elements within the first 150 bp of the promoter that are bound by nuclear proteins; one of them is NF-KB (53).
The B7.1 Enhancer is Cell Type Specific and Inducible by cAMP and LPS.
B7.1 expression is strictly cell type specific. To test the tissue specificity of the enhancer region defined above, transient transfections of several constructs which include this region were performed (Fig. 5 A) . Cell lines tested included the B7.1-negative Jurkat T lymphoma and HeLa epithelial carcinoma and the B7.1-positive human B Lymphoma BA (54) . The 585-, 282-, and 183-bp constructs shown to be active in the B7.1-positve kaji B cell line (Fig. 4 A) cells, this 183-bp region is cell type specific. Additional B7.1-negative cell lines (Hut78 T cell and G82 glioblastoma) also showed no activity (data not shown). Some modest (about twofold) enhancer activity was observed in a B7.1-negative pre-B cell line Nalm 6 with these constructs, but no activity was present when the longer 1.3-, 1.9-, and 3.7-kb constructs were used (data not shown). This suggests that in B7.1-negative B cells, there may also be a role for negative elements, outside of the 183-bp enhancer, in mediating tissue specificity. We conclude that the enhancer located at DH site B within the 183-bp StuI-ApaI fragment is cell type specific. Multiple stimuli increase B7.1 expression in B cells and macrophages. We have previously shown that the M12 cell line expresses low levels of cell surface B7.1 that can be markedly increased by treatment with db-cAMP (27) . Treatment of M12 with 30 ~g/ml db-cAMP after transfection of the 585-, 282-, and 183-bp constructs results in a modest but reproducible increase in CAT activity (Fig. 5 B) . We were also able to test the induction of transcription activity of the enhancer by LPS in both M12 and in the mouse B7.1-positive myeloblast/monocyte-like cell line M1. Treatment of these cell lines with LPS for 48 h results in a modest but reproducible increase in both surface B7.1 expression for M1 (not tested for M12) (Fig. 5 C, left) and CAT activity in both cell lines (Fig 5 C, right and Fig.5 D) .
We also tested the native B7.1 promoter fused to the 486-bp enhancer in the M12 cell line. Induction of transcription by LPS was also observed in this instance (Fig. 5 D) . We conclude that elements within the 183-bp region confer responsiveness to stimuli known to increase B7.1 expression. Further, enhancer activity is not limited to cells of the B lineage, but can be observed in B7.1-positive, non-B cells, including the HTLV-l-transformed B7.1-positive T cell MT2 (data not shown). We could not examine other stimuli such as IL-4 or Abs to CD40, known to induce B7.1 expression in B cells, because of the absence of appropriately inducible, transfectable cell lines. To establish whether this enhancer region also controls responsiveness to other stimuli such as IL-4 and anti-CD40 may require the production of mice transgenic for the enhancer to allow the examination of B7.1 regulation in normal cells. (Fig.   6 A) employing a series of enhancer deletion constructs with subsequent transfection into Raji cells revealed that nucle- otides at both the 5' (lanes 5 and 7) and 3' (lanes 3 and 7) ends of the enhancer were impo~nt. Furthermore, sequences internal to these were also involved in enhancer activity (compare lanes 5 with 6 and lanes 3 with 4). Thus, multiple cis elements appeared to be present within the 183-bp fragment. To precisely delineate the sequences within the 183-bp region responsible for enhancer function, linkerscanning mutagenesis was performed. Each linker-scanning mutation was 10 bp in length with the exception ofmut 18 which was 13 bp in length. Several bases in the 10-bp stretch were mutated to one of the three remaining nucleotides (see Fig. 6 B) with each resulting sequence checked to ascertain that no known promoter motif had been inadvertently created. The wild-type and mutation constructs were transfected into the R.aji cell line and the results of three to five independent experiments are shown in hancer, whereas three additional mutations (mut 4, 9, and 12) also reproducibly decreased enhancer activity in five independent experiments. The locations of these mutations (Fig. 6 B) are consistent with the deletion data in Fig. 6 A. Several additional mutations also modestly decreased activity (mut 3, 5, and 17). Inspection of the mut 2, 4, 9, 12, and 16 sequences (Fig. 6 D) reveals that site 16 is a consensus NF-KB element that is identical both in its core nudeotides and in the flanking nucleotides to the NF-KB site in the IgK enhancer. Mutation of this element resulted in >70% abolition of enhancer activity. The remaining four sequences do not bear homology to known promoter motifs as checked against sequences in the database. A sequence with a 7/8 nucleotide match to a cAMP response element is also present in the enhancer, but mutation of this element (rout 3) has minimal effect on enhancer activity in 1Kaji cells.
Deletional and Mutational Analysis of the 183-bp Enhancer Reveals Several Functional cis Elements. Initial experiments

Members of the NF-KB Family Bind to the B7.1 NF-KB Site.
Using an oligonucleotide corresponding to the consensus NF-KB element mutated in site 16 as a probe, EMSAs were performed with nuclear extracts from the B7.1-positive Raji cell hne (Fig. 7 A, le~) . A DNA-protein complex could be observed with extracts from 1Kaji ( Fig. 7 A) , but not with nuclear extracts from Jurkat (not shown) that migrates similarly to a complex observed with the IgK NF-KB site (Fig.7, right) . That this complex was specific was shown by the ability of a 10-100-fold molar excess of unlabeled wild-type NF-KB oligonucleotides, but not an oligonucleotide from the unrelated IL-4 promoter, to prevent complex formation (Fig. 7 A) . The multimember NF-KB ramfly includes homologous proteins termed p50, p52, p65, c-lKel, and IKelB. Various combinations of homo-and heterodimers of these family members may activate or repress NF-KB-dependent gene transcription (55, 56) . To determine which family members present in Raji cells bound to this site, supershift EMSA experiments were performed using antisera to the p50, p52, p65, c-IKel, and RelB proteins. Fig. 7 B demonstrates that two complexes can be observed (arrows). The faster migrating lower complex (Fig. 7 B, /) is supershifted by Abs to p50, c-Rel, and 1KelB, suggesting it is a homo-or heterodimer of these proteins whereas the slower migrating upper complex (I/) is supershifted by the Abs to p50 and p65, suggesting it is a heterodimer composed of p50 and p65 proteins. Such homoand heterodimers of various NF-KB family members have been previously observed to bind NF-KB target sequences in many promoters (47, 57, 58) . The p52 protein is not involved in binding to the B7.1 NF-KB site as judged by the failure of the anti-p52 Ab to affect complex formation. Cotransfection of M12 B cells with the 183-bp enhancer and NF-KB subunits p50 or p65 expression constructs demonstrated that p65 transactivates the enhancer, whereas p50 does not (Fig. 7 C) . Further, p50 decreases transactivation by p65, consistent with the known role of p65 as a transcriptional activator and p50 as a repressor. This is the first description to our knowledge of regulatory elements that control expression of the gene encoding the B7.1 costimulatory molecule. The presence of a tissuespecific DNase I hypersensitive site N3 kb upstream of the transcription start site of the human B7.1 gene led to the identification of a cell type-specific enhancer region. This 183-bp region was both cell type specific and responsive to two distinct stimuli (LPS and db-cAMP) known to regulate B7.1 expression. Site-directed mutagenesis revealed the presence of multiple cis elements within this region, one of which was a NF-KB consensus sequence. This element binds The NF-rd3 family of transcription factors has been shown to be critical for cell development, differentiation, and the response to multiple stimuli. The five members of this fami l y -p 5 0 , p52, p65, c-Rel, and R e l B --a l l contain a R e lhomology domain required for binding to D N A . NF-KB members are present ubiquitously in the cytosol of many different cell types where they form a stable complex with the Imt3ot and Ir inhibitor proteins (59, 60) . Activation by mitogenic factors leads to phosphorylation and degradation of IKB and subsequent translocation of NF-KB proteins into the nucleus (61) (62) (63) (64) . Various h o m o -and heterodimers o f nuclear NF-KB members are potent transactivators or repressors for many developmentally regulated genes. B7.1 expression is also developmentally regulated and responsive to stimuli known to increase nuclear NF-KB activity. These stimuli include LPS (65), cross-linking of CD40 on B cells by soluble CD40 ligand (66, 67) , or ligation of B cell surface Ig (68) . The induction of NF-KB activity in T cells is regulated by HTLV-1 Tax (69). Mature activated B cells which contain constitutive nuclear NF-KB activity are the major site o f expression of B7.1 (56, 70, 71) . Thymic dendritic cells, the other cell type that constitutively expresses B7.1, are critically dependent of R e l -B activity since Rel B-deficient mice have recently been shown to lack mature dendritic cells (72) . Thus, B7.1 expression appears to parallel NF-KB activity, consistent with a convergence of signal transduction for BT.l-inducing stimuli on this family of transcription factors. However, our data clearly indicate that other cis elements also control B7.1 expression. Several additional cis elements with no obvious homology to known promoter motifs were critical for functional enhancer activity. N o w that a BT.l-specific enhancer that functions in concert with a mimimal promoter has been delineated, identification of the factors that bind to these additional elements will be key in further understanding the regulation of this important costimulatory molecule.
